These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34021484)

  • 1. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature.
    Zhou Y; Liao S; You J; Wu H
    Updates Surg; 2022 Feb; 74(1):43-53. PubMed ID: 34021484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis.
    Lindemann J; du Toit L; Kotze U; Bernon M; Krige J; Jonas E
    HPB (Oxford); 2021 Feb; 23(2):173-186. PubMed ID: 33268268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
    Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
    Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.
    Klaiber U; Schnaidt ES; Hinz U; Gaida MM; Heger U; Hank T; Strobel O; Neoptolemos JP; Mihaljevic AL; Büchler MW; Hackert T
    Ann Surg; 2021 Jan; 273(1):154-162. PubMed ID: 30921051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preceding Systemic Chemotherapy for Patients with Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology Provides Survival Benefit Compared with Up-Front Surgery.
    Ariake K; Mizuma M; Motoi F; Maeda S; Morikawa T; Ishida M; Ohtsuka H; Aoki S; Miura T; Takadate T; Nakagawa K; Kamei T; Unno M
    Ann Surg Oncol; 2021 Oct; 28(11):6246-6254. PubMed ID: 33611747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma.
    Yanagimoto H; Satoi S; Yamamoto T; Yamaki S; Hirooka S; Kotsuka M; Ryota H; Ishida M; Matsui Y; Sekimoto M
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer.
    Okano K; Suto H; Oshima M; Ando Y; Nagao M; Kamada H; Kobara H; Masaki T; Okuyama H; Okita Y; Tsuji A; Suzuki Y
    Jpn J Clin Oncol; 2018 May; 48(5):434-441. PubMed ID: 29590448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant surgical therapy for patients with initially-unresectable pancreatic cancer with long-term favorable responses to chemotherapy.
    Kato K; Kondo S; Hirano S; Tanaka E; Shichinohe T; Tsuchikawa T; Matsumoto J
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):712-6. PubMed ID: 21455748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis.
    Mataki Y; Kurahara H; Idichi T; Tanoue K; Hozaka Y; Kawasaki Y; Iino S; Maemura K; Shinchi H; Ohtsuka T
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma.
    Shimomura O; Oda T; Hashimoto S; Doi M; Hiroshima Y; Numajiri H; Takahashi K; Furuya K; Miyazaki Y; Owada Y; Ogawa K; Ohara Y; Hisakura K; Akashi Y; Enomoto T; Sakurai H
    Surg Oncol; 2021 Jun; 37():101542. PubMed ID: 33740629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study.
    Kamarajah SK; White SA; Naffouje SA; Salti GI; Dahdaleh F
    Ann Surg Oncol; 2021 Oct; 28(11):6790-6802. PubMed ID: 33786676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series.
    Feo CF; Deiana G; Ninniri C; Cherchi G; Crivelli P; Fancellu A; Ginesu GC; Porcu A
    World J Surg Oncol; 2021 Apr; 19(1):126. PubMed ID: 33866970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
    de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
    Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Review.
    Datta J; Willobee BA; Ryon EL; Shah MM; Drebin JA; Kooby DA; Merchant NB
    JAMA Surg; 2021 May; 156(5):489-495. PubMed ID: 33533898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma.
    Sadot E; Doussot A; O'Reilly EM; Lowery MA; Goodman KA; Do RK; Tang LH; Gönen M; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2015 Oct; 22(11):3512-21. PubMed ID: 26065868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.